Holen Sie sich die Stockscreener-App
26.45
1.12%
-0.30
Schlusskurs vom Vortag:
$26.75
Offen:
$26.505
24-Stunden-Volumen:
4.36M
Relative Volume:
0.60
Marktkapitalisierung:
$18.93B
Einnahmen:
$125.68M
Nettoeinkommen (Verlust:
$4.81B
KGV:
4.6814
EPS:
5.65
Netto-Cashflow:
$-781.21M
1W Leistung:
+2.44%
1M Leistung:
+12.84%
6M Leistung:
+121.15%
1J Leistung:
+153.11%
1-Tages-Spanne:
$26.23
$26.83
1-Wochen-Bereich:
$25.72
$27.94
52-Wochen-Spanne:
$8.73
$27.94
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
26.45 | 19.15B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-02 | Eingeleitet | Citigroup | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-17 | Eingeleitet | Guggenheim | Buy |
| 2023-06-08 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-27 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Eingeleitet | Goldman | Buy |
| 2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-28 | Eingeleitet | Citigroup | Buy |
| 2021-10-26 | Eingeleitet | Cowen | Outperform |
| 2021-10-26 | Eingeleitet | Jefferies | Buy |
| 2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data - Insider Monkey
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 375,784 Shares of Stock - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 425,000 Shares - MarketBeat
Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out - The Motley Fool
HC Wainwright Analysts Increase Earnings Estimates for ROIV - MarketBeat
Is Roivant Sciences Ltd. stock undervalued right now2025 Short Interest & AI Based Buy and Sell Signals - mfd.ru
Can Roivant Sciences Ltd. lead its sector in growthLayoff News & Detailed Earnings Play Alerts - mfd.ru
EV Market: What is IROQs debt to equity ratioJuly 2025 Snapshot & Verified Momentum Stock Watchlist - baoquankhu1.vn
Roivant Sciences (NASDAQ:ROIV) Insider Sells $8,985,003.27 in Stock - MarketBeat
Impax Asset Management Group plc Sells 200,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Why Roivant Sciences Ltd. (87S) stock appeals to dividend investors2025 Performance Recap & Expert Curated Trade Ideas - mfd.ru
Candriam S.C.A. Increases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock price target raised to $33 from $26 at H.C. Wainwright - Investing.com Australia
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV)Here's Why - Finviz
Citi raises Roivant Sciences stock price target to $35 from $26 - Investing.com Australia
Citi raises Roivant Sciences stock price target to $35 from $26 By Investing.com - Investing.com South Africa
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs By Investing.com - Investing.com South Africa
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs - Investing.com India
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) – Here’s Why - Insider Monkey
Roivant Sciences Earnings Call Highlights Brepocitinib Surge - TipRanks
Roivant Sciences stock hits all-time high at 26.35 USD By Investing.com - Investing.com Nigeria
Deep Dive Into Roivant Sciences Stock: Analyst Perspectives (4 Ratings) - Benzinga
Roivant Sciences stock hits all-time high at 26.35 USD - Investing.com
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib phase III launch in 2026 - MSN
Roivant Sciences (ROIV) Valuation Check After Strong Share Price Momentum - Yahoo Finance
Looking At The Narrative For Roivant Sciences ROIV After 2026 Catalyst And Litigation Shifts - Yahoo Finance
Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next - TechStock²
Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio?Lumentum Holdings (NASDAQ:LITE), Oshkosh (NYSE:OSK), Roivant Sciences (NASDAQ:ROIV), Regal Rexnord (N - Benzinga
Roivant Sciences Ltd. $ROIV Shares Bought by New York State Common Retirement Fund - MarketBeat
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative - simplywall.st
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday - TechStock²
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress - Finviz
Roivant Sciences earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
10 Easy Double-Digit Gainers - Insider Monkey
Roivant Sciences Q3 2026 Earnings Call Transcript - MarketBeat
Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight - GuruFocus
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade) - Seeking Alpha
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum - Investing.com Nigeria
Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss - simplywall.st
Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Earnings call transcript: Roivant Sciences misses Q3 2026 estimates despite stock surge - Investing.com Canada
Why Is Roivant Stock Trading Higher Today?Roivant Sciences (NASDAQ:ROIV) - Benzinga
Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year HighStill a Buy? - MarketBeat
Roivant Sciences Q3 Earnings Call Highlights - MarketBeat
Immunovant Q3 Earnings Call Highlights - Yahoo Finance
ROIV: Strong phase II data for brepocitinib in cutaneous sarcoidosis; multiple pivotal readouts ahead - TradingView
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum By Investing.com - Investing.com South Africa
Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib - Nasdaq
Roivant Sciences stock soars after positive cutaneous sarcoidosis trial data By Investing.com - Investing.com Australia
Pfizer-backed Priovant posts positive data for lead asset (PFE) - Seeking Alpha
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):